Abstract Types

Clinical Review Abstract

Late-Breaking Abstract

Trials in Progress Abstract

Abstracts selected for publication but not presentation at the Annual Meeting

Abstracts granted an exception in accordance with ASCO's Conflict of Interest Policy

Safety and efficacy of 90y resin microspheres in elderly (≥70 years) compared to younger patients with colorectal liver metastases (mCRC).

Colorectal Cancer

Gastrointestinal (Colorectal) Cancer

2013 ASCO Annual Meeting

Abstract No:

J Clin Oncol 31, 2013 (suppl; abstr e14545)

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Andrew S. Kennedy, David Ball, Steven J. Cohen, Michael Cohn, Douglas M. Coldwell, Alain Drooz, Edward Ehrenwald, Samir Kanani, Fred M Moeslein, Charles W. Nutting, Samuel G. Putnam, Steven C. Rose, Michael Savin, Sabine Schirm, Navesh K Sharma, Eric Wang; Sarah Cannon Research Institute, Nashville, TN; Fox Chase Cancer Center, Philadelphia, PA; Radiology Associates of Hollywood, Pembroke Pines, FL; James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Fairfax Radiological Consultants, Fairfax, VA; Abbott Northwestern Hospital, Minneapolis, MN; Inova Fairfax Hospital, Annandale, VA; University of Maryland Medical Center, Baltimore, MD; Radiology Imaging Associates, Englewood, CO; UC San Diego Moores Cancer Center, La Jolla, CA; Beaumont Hospital, Royal Oak, MI; Cancer Centers of North Carolina, Cary, NC; University of Maryland School of Medicine, Baltimore, MD; Charlotte Radiology, Charlotte, NC

Abstract Disclosures


Background: The effects of advanced age on the clinical outcomes following 90Y treatment in elderly patients with mCRC are relatively unknown. Methods: A retrospective review was conducted to evaluate clinical outcomes among 160 elderly (≥70 years) and 446 younger (<70 years) patients with unresectable mCRC consecutively treated using 90Y resin microspheres (SIR-Spheres; Sirtex) from July 2002 to December 2011 at 11 US institutions. Data on background characteristics, prior chemotherapy or other procedures, 90Y therapy, subsequent adverse events and survival were documented. Results: The mean age (+ SD) of the elderly patients was 77.2 + 4.85 years and 55.9 + 9.45 years in the younger cohort. Regardless of age, patients receiving 90Y treatment were very similar in the elderly and younger cohorts in terms of sex, race, ECOG performance status and other characteristics. However, elderly patients were more likely to have had their primary resected (7.1% vs. 15.1%; p=0.009), received fewer lines of chemotherapy (p=0.036; 13.1% vs. 2.8% had no prior chemo, p<0.001), a longer period between diagnosis and 90Y therapy (median 26.9 vs. 20.5 months; p=0.011), and received only one 90Y treatment (58.8% vs. 46.4%; p=0.007). Overall survival following 90Y therapy did not deteriorate in elderly patients (median 9.3 vs. 9.7 months; p=0.335). 90Y treatment was equally well tolerated in both cohorts, with no significant increase in grade 3+ adverse events in elderly patients, but significantly fewer grade 1+ events for abdominal pain (26.3% vs. 41.3%; p<0.001) and nausea (20.6% vs. 29.4%; p=0.038). The most common grade 3+ events included: abdominal pain (3.1% vs. 6.1%), GI ulceration 0.6% vs. 1.3%), nausea (0.6% vs. 1.3%), vomiting (1.3% vs. 1.3%), fatigue (5.6% vs. 4.5%), ascites (1.3% vs. 2.0%), hyperbilirubinemia (3.8% vs. 2.7%) and anorexia (0.6% vs. 0.9%). Analysis of the 98 patients ≥75 years compared to younger patients confirmed equivalent outcomes for survival and toxicity. Conclusions: For patients with unresectable mCRC liver metastases that meet eligibility criteria, 90Y therapy appears to be as effective and well-tolerated for the elderly as it is for younger candidates.


  Other Abstracts in this Sub-Category:


1. Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial.

Meeting: 2013 ASCO Annual Meeting Abstract No: 3500 First Author: D. Mant
Category: Gastrointestinal (Colorectal) Cancer - Colorectal Cancer


2. Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study.

Meeting: 2013 ASCO Annual Meeting Abstract No: 3501 First Author: C. L. Loprinzi
Category: Gastrointestinal (Colorectal) Cancer - Colorectal Cancer


3. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).

Meeting: 2013 ASCO Annual Meeting Abstract No: 3502 First Author: M. Koopman
Category: Gastrointestinal (Colorectal) Cancer - Colorectal Cancer